Welcome to our dedicated page for Tenaya Therapeutics SEC filings (Ticker: TNYA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tenaya Therapeutics filings document a clinical-stage biotechnology issuer focused on genetic and small-molecule approaches to heart disease. Recent 8-K reports furnish operating results and corporate updates tied to TN-201, TN-401 and TN-301, including clinical and regulatory disclosures for cardiomyopathy programs and research updates for cardiovascular target validation.
The company’s SEC record also includes definitive proxy materials for annual-meeting governance and shareholder voting matters, material-agreement disclosure for its cardiovascular target research collaboration, capital-structure information and Nasdaq continued-listing compliance disclosures. These filings frame Tenaya’s public reporting around pipeline development, financing capacity, governance and common stock status.
Tenaya Therapeutics, Inc. granted new equity awards to SVP, Finance Tomohiro Higa. On February 3, 2026, he received 29,250 shares of common stock in the form of restricted stock units, issued at $0 and bringing his directly held common stock (including unvested RSUs) to 123,221 shares.
Higa also received a stock option for 175,500 shares of common stock with an exercise price of $0.915 per share, expiring on February 2, 2036. The option vests in equal monthly installments over 48 months starting one month after the grant date, while the new RSUs vest in eight equal installments every six months beginning August 15, 2026.
Tenaya Therapeutics, Inc. reported new equity awards to its Chief Medical Officer, Tingley Whittemore. On 02/03/2026, Whittemore received 48,750 restricted stock units under the 2021 Equity Incentive Plan. These RSUs vest 1/8 on August 15, 2026, with additional 1/8 installments every six months until fully vested.
On the same date, Whittemore was also granted a stock option for 318,500 shares of common stock at an exercise price of $0.915 per share, vesting in 48 equal monthly installments starting one month after the grant date. Following these transactions, Whittemore beneficially owned 223,778 shares of common stock, including 134,588 shares underlying RSUs.
Tenaya Therapeutics, Inc. reported an equity award grant to its Chief Executive Officer, Ali Faraz. On February 3, 2026, he received 158,600 shares of common stock in the form of restricted stock units at a price of $0 per share, which will vest in installments beginning August 15, 2026 and then every six months until fully vested. He also received a stock option for 952,250 shares of common stock at an exercise price of $0.915 per share, vesting monthly over four years starting one month after the grant date. Following these grants, he beneficially owned 458,266 shares of common stock, including 369,875 shares underlying restricted stock units, and 952,250 stock options, all held directly.
Tenaya Therapeutics, Inc. received a notice from Nasdaq that its common stock has failed to meet the minimum $1.00 bid price requirement for the last 30 consecutive business days through January 27, 2026. The company has a 180‑day compliance period, until July 27, 2026, to restore its share price to at least $1.00 for a minimum of ten consecutive business days or risk delisting from the Nasdaq Global Select Market.
If compliance is not regained, Tenaya may seek a transfer to the Nasdaq Capital Market and potentially receive a second 180‑day cure period, subject to additional conditions and Nasdaq approval. Separately, the Board amended and restated the 2024 Inducement Equity Incentive Plan, reserving an additional 2,161,000 shares, bringing the aggregate reserve to 3,361,000 shares for inducement and acquisition‑related equity awards to new hires and qualifying individuals.
Tenaya Therapeutics is raising capital by offering 50,000,000 units in an underwritten public stock and warrant sale. Each unit is priced at $1.20 and includes one share of common stock and one five-year warrant to buy a share at $1.50, with underwriters purchasing at $1.128 per unit. The transaction is expected to generate approximately $60 million in gross proceeds and is scheduled to close on December 15, 2025, subject to customary conditions.
The warrants can be exercised for cash, or on a cashless basis if no effective registration statement covers the underlying shares, and adjust for stock splits and similar events. Exercises are limited so that, after giving effect to an exercise, a holder (together with its affiliates) cannot exceed 4.99% or, if elected, 9.99% of Tenaya’s outstanding common stock or combined voting power, with the percentage adjustable, upon at least 61 days’ notice, to a level not above 19.99%. The company, its officers and directors, and certain shareholders have agreed to a 60-day lock-up, and the deal is being conducted under an already effective shelf registration statement.
Tenaya Therapeutics is offering 50,000,000 units in an underwritten public sale, each unit consisting of one share of common stock and a five-year warrant to purchase one share at an exercise price of $1.50. The units are priced at $1.20, for gross proceeds of $60,000,000 and estimated net proceeds of approximately $55.8 million after underwriting discounts and expenses.
The company’s common stock trades on the Nasdaq Global Select Market under the symbol TNYA, while the Warrants will not be listed and have ownership caps of 4.99% or 9.99%, adjustable up to 19.99% with notice. Net proceeds, together with existing cash and investments, will fund ongoing and planned development of lead gene therapy candidates TN‑201 and TN‑401 and other pipeline work, plus working capital and general corporate purposes. As of September 30, 2025, Tenaya had 163,744,535 shares of common stock outstanding, so investors in this deal will experience immediate dilution, including an estimated $0.55 per-share dilution based on the offering terms.
Tenaya Therapeutics, Inc. (TNYA) reported an insider transaction by its SVP, Finance. On 11/17/2025, the officer sold 1,367 shares of common stock at a price of $1.33 per share, coded as a sale to satisfy obligations. The filing explains that the shares were sold to cover tax withholding related to the vesting of restricted stock units granted on August 15, 2024.
After this transaction, the reporting person beneficially owns 93,971 shares of Tenaya Therapeutics common stock. This total includes 50,470 shares that will be issued upon the vesting of restricted stock units in the future.
Tenaya Therapeutics, Inc. reported an insider transaction by its Chief Medical Officer. On 11/17/2025, the officer sold 2,877 shares of Tenaya common stock at $1.33 per share. The sale was made to cover tax withholding obligations related to the vesting of restricted stock units that were originally granted on January 24, 2025.
After this transaction, the officer beneficially owned 169,926 shares of Tenaya common stock, including 85,838 shares that will be issued upon the vesting of restricted stock units. The filing is a routine Form 4 disclosure of insider equity activity.
Tenaya Therapeutics, Inc. reported a routine insider transaction by its Chief Executive Officer, who is also a director. On 11/17/2025, the reporting person sold 3,126 shares of Tenaya Therapeutics common stock at a price of $1.33 per share. According to the filing, these shares were sold to cover tax withholding obligations tied to the vesting of restricted stock units originally awarded on February 6, 2025.
After this tax-related sale, the reporting person beneficially owned a total of 299,666 shares of Tenaya Therapeutics common stock. This total includes 211,275 shares that will be issued upon the future vesting of restricted stock units. The filing indicates that the ownership is held directly by the reporting person.
Tenaya Therapeutics (TNYA) reported Q3 2025 results. Net loss was $20.3 million, improving from $25.6 million a year ago, as operating expenses fell to $20.9 million from $26.7 million. Research and development declined to $15.4 million and general and administrative to $5.6 million. Interest income was $0.7 million.
Cash and cash equivalents were $56.3 million, with total assets of $105.0 million and stockholders’ equity of $82.9 million as of September 30, 2025. For the nine months, net loss was $70.4 million versus $87.3 million in 2024. The company completed a March 2025 follow‑on offering with net proceeds of approximately $48.8 million and raised $0.9 million via at‑the‑market sales in January. An SVB loan agreement provides the right to draw $10.0 million through December 31, 2025, with up to an additional $20.0 million at the lender’s discretion.
Programs advanced with interim TN‑201 data presented in November; the FDA placed MyPEAK‑1 on clinical hold to standardize monitoring and immunosuppression protocol activities. Tenaya recognized $1.5 million from an $8.0 million CIRM grant for TN‑401 and recorded $1.2 million related to a 2025 workforce reduction. The company believes existing resources, potential loan availability, and recent warrant exercises will fund operations for at least twelve months following filing. Shares outstanding were 166,505,885 as of November 4, 2025.